StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

Equities researchers at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Price Performance

NYSE ENZ opened at $1.13 on Thursday. Enzo Biochem has a 52 week low of $0.99 and a 52 week high of $1.50. The company has a 50-day moving average price of $1.13 and a 200-day moving average price of $1.12.

Institutional Investors Weigh In On Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. Renaissance Technologies LLC lifted its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 2.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,499,546 shares of the medical research company’s stock after buying an additional 64,417 shares during the quarter. Renaissance Technologies LLC owned about 4.86% of Enzo Biochem worth $2,725,000 as of its most recent filing with the Securities & Exchange Commission. 36.90% of the stock is currently owned by hedge funds and other institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.